華體科技(603679.SH)擬與人華智聯(重慶)共設合資公司 及在德陽設立全資子公司
格隆匯 12 月 29日丨華體科技(603679.SH)公佈,公司召開第三屆董事會第三十三次會議,審議通過《關於對外投資的議案》。
1.為開拓重慶市5G多杆合一智慧路燈市場,公司與人華智聯(重慶)科技有限公司經過友好協商,同意共同出資設立合資公司重慶華體科技創新中心有限公司,合資公司註冊資本為1000萬元人民幣,其中,公司股份比例為65%,人華智聯(重慶)科技有限公司股份比例為35%。
2.為更好地提高公司產能,公司擬在德陽設立全資子公司德陽華智精密科技有限公司,註冊資本5000萬元人民幣,以公司自有資金出資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.